^
Association details:
| Biomarker: | FGFR2 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | KIN-3248 (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
Published date:
02/14/2023
Excerpt:
Kinnate Biopharma...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kinnate’s investigational pan-FGFR inhibitor, KIN-3248, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other alterations, who have received at least one prior systemic therapy.
